**Core tip:** Endoscopic balloon dilation (EBD) for Crohn's disease-related fibrostenotic strictures has been recognized as a safe, and less invasive intervention with rare complications that occur in less than 3% of procedures. EBD can replace or defer surgery and help avoid frequent intestinal resections, which result in short bowel syndrome and impair quality of life. For non-complex strictures without adjacent fistulization or perforation that are less than 5 cm in length, EBD should be considered as first-line therapy. In this review we discuss safety, short and long-term outcomes, as well as adjuvant techniques of intralesional injection of steroids, anti-tumor necrosis factor, and metal stent insertion.

INTRODUCTION
============

Intestinal strictures are a common complication of Crohn's disease (CD) affecting one-third of the patient population within 10 years of disease onset. This number, however, is likely under-reported\[[@B1],[@B2]\]. In general, CD strictures are classified into inflammatory, fibrotic or mixed, although all symptomatic inflammatory strictures likely have some component of fibrosis and vice-versa\[[@B2],[@B3]\]. Risk factors and predictors of intestinal strictures to date are clinical, environmental, genetic or endoscopic parameters\[[@B4]\] (Table [1](#T1){ref-type="table"}). Although no clinical factors exist which can accurately predict the stricturing phenotype of CD, there do exist factors which may predict the likelihood of small bowel disease and a disabling disease course thus indirectly may suggest an increased risk for the development of fibrostenotic disease. These factors include the presence of perianal disease, age of CD diagnosis less than 40 years old and the need for steroids during the first flare\[[@B4],[@B5]\]. Patients frequently complain of progressive post-prandial abdominal pain, bloating, nausea, vomiting and weight loss. The diagnosis of intestinal strictures usually coincides with a spiraling decline in quality of life and results in surgery in 75% of patients at least once during their lifetime\[[@B1]\]. CD patients will frequently undergo multiple bowel resections over their lifetime that repeatedly exposes them to immediate and long-term post-operative complications such as anastomotic leaks with intra-abdominal sepsis, short bowel syndrome, and adhesions with recurrent bowel obstructions\[[@B2],[@B6]\].

###### 

Risk factors and predictors of fibrostenosing Crohn's disease

  ----------------------------------------------------------------- -------------------------------------------------------
  Clinical\[[@B4]\]                                                 Age at diagnosis \< 40 yr
  Perianal disease at diagnosis                                     
  Need for steroids during first flare                              
  Small bowel disease location                                      
  Prior appendectomy                                                
  Environmental\[[@B4]\]                                            Smoking
  Endoscopic\[[@B4]\]                                               Deep mucosal ulcerations
  Genetic\[[@B4]\]                                                  Nucleotide oligomerisation domain 2 (*NOD2*) variants
  Janus-associated kinase 2 (*JAK2*)                                
  Caspase-recruitment domain 15 (*CARD15*)                          
  *NOD2*/*CARD15* mutations on both chromosomes                     
  TNF superfamily 15 (*TNFSF15*) in Asians                          
  5T5T in the *MMP3* gene                                           
  rs1363670                                                         
  Serological\[[@B4]\]                                              Antimicrobial antibodies
  anti-*Saccharomyces cerevisiae* antibodies (ASCA) IgA in Asians   
  ----------------------------------------------------------------- -------------------------------------------------------

The pathogenesis of CD complications develops from chronic accumulation of inflammatory bowel damage variably leading to stricture, fistula and/or abscess formation\[[@B2]\]. Stricture development, although not fully understood, involves the progressive deposition of extracellular matrix protein (ECM) produced by myofibroblasts at variable sites of the bowel being injured by chronically uncontrolled relapsing and remitting transmural inflammation\[[@B7]\]. During chronic intestinal inflammation, the baseline release of profibrotic cytokines (*e.g*., IL-4 and IL-13) increases over time further accelerating the process of excessive matrix deposition\[[@B7],[@B8]\]. There may also exist a point where inflammation is no longer required to trigger fibrosis. As ECM is deposited during chronic inflammation, the bowel wall becomes stiffer. Bowel wall stiffness acts independently as a mesenchymal cell activator, resulting in ongoing myofibroblast stimulation, thus progressive fibrotic stenosis\[[@B9]\].

Treatment options for fibrostenotic strictures are limited to endoscopic and surgical therapy (*i.e*., stricturoplasty and small bowel resection)\[[@B10]\]. Fortunately, most *de novo* strictures form in the ileum and ileocolic regions, which are accessible by ileocolonoscopy or balloon-assisted enteroscopy\[[@B11]\]. Although pharmacotherapy may delay the time before operative management, it has not been shown to prevent it\[[@B12]\]. Approximately 80% of patients will have their first bowel resection 10 years following their diagnosis of CD\[[@B2]\]. To date no specific intestinal anti-fibrotic therapy exists, nor has any immunosuppressant or biologic therapy been shown to prevent stricture formation.

The following review presents the current data on the endoscopic management of small bowel and colonic strictures in CD. Short and long-term outcomes, complications and a description of the procedure will be discussed.

EFFICACY OF ENDOSCOPIC BALLOON DILATION
=======================================

Endoscopic balloon dilation (EBD) is a minimally invasive bowel-length preserving mean of managing symptomatic CD patients with short fibrotic strictures (Figure [1](#F1){ref-type="fig"}). EBD has become an established modality of therapy and often plays an important role in delaying or acting as a bridge to surgery\[[@B10],[@B13]\]. The most common location of the small bowel to undergo EBD using a colonoscope is the distal ileum or at the ileocolonic anastomosis of a patient following a small bowel resection\[[@B14]\]. Strictures located in the distal duodenum to proximal jejunum or distal jejunum to proximal ileum may be accessed with ante- or retrograde enteroscopy, respectively\[[@B15]\].

![Endoscopic balloon dilatation of ileocolonic anastomosis (A) and endoscopic appearance post endoscopic dilatation (B).](WJG-24-1859-g001){#F1}

Short- and long-term efficacy has been inconsistently defined in studies\[[@B13]\]. In general, short-term efficacy has been described as the technical success of the procedure or the ability to traverse the dilated area freely with the endoscope immediately after dilatation\[[@B13],[@B16]\]. Long-term efficacy, in most studies, has been described as the time elapsed until another intervention (either surgical or endoscopic) is required\[[@B2],[@B13],[@B16]\]. Despite the lack of a formal definition, excellent short- and moderate long-term efficacy of EBD for CD strictures has been documented in many studies\[[@B14],[@B16],[@B17]\]. Table [2](#T2){ref-type="table"} shows a summary of published studies on EBD using conventional colonoscopy in CD patients. In a systematic review and descriptive pooled analysis of 12 studies conducted between 1991 to 2013 evaluating 1463 CD patients who underwent 3213 EBD procedures, the technical success rate was 89% with an associated relief of clinical symptoms in 81% of patients\[[@B14]\]. The majority of strictures were ileal (98.6%) at anastomotic sites (62%), which were 2 *cm* or less. However, the recurrence rate of strictures was high. At the 36.6 mo median follow-up, 47.5% of patients had symptomatic recurrence and 28.6% of all patients had required surgical intervention. This study concluded that the chance of requiring repeat EBD or surgical intervention at 2 years was 73.5% and 42.9%, respectively\[[@B14]\]. Another large recent systematic review with meta-analysis involving 1089 patients (2664 EBDs) across 25 studies revealed similar results\[[@B17]\]. The technical success rate was 92.3% with a reported symptomatic response rate of 70.4%. The proportion of patients requiring a repeat dilation after 1 and 2 years was 31.6% (160/506) and 25.9% (117/451), respectively. Most patients within 5 years required recurrent dilations (80%) and/or surgical interventions (75%)\[[@B17]\]. Of interest is the lower symptomatic success rate as compared to the technical success rate across studies. This likely occurred due to a lack of a standardized means of reporting technical and clinical efficacy and/or a superimposed process existing that contributed to the patient's symptoms (*e.g*., ongoing inflammation, intestinal bacterial overgrowth, IBS, *etc*.)\[[@B10]\]. Despite this discrepancy, the short-term clinical success rate remains high.

###### 

Summary of published studies on endoscopic balloon for Crohn's disease strictures

  **Authors**                     **Pubished year**   **No. of patients**   **Anastomotic strictures (%)**   **Maximum balloon caliber (mm)**   **Technical success (%)**   **Clinical efficacy (%)**   **Major complication (%)**
  ------------------------------- ------------------- --------------------- -------------------------------- ---------------------------------- --------------------------- --------------------------- ----------------------------
  Blomberg et al\[[@B52]\]        1991                27                    100                              25                                 100                         67                          0
  Williams et al\[[@B53]\]        1991                7                     71                               20                                 71                          71                          0
  Breysem et al\[[@B54]\]         1992                18                    78                               18                                 89                          50                          0
  Cockuyt et al\[[@B55]\]         1995                55                    67                               20                                 85                          62                          8
  Ramboer et al\[[@B56]\]         1995                13                    69                               18                                 100                         100                         0
  Matsui et al\[[@B57]\]          2000                55                    43                               20                                 86                          78                          2
  Dear et al\[[@B58]\]            2001                22                    95                               18                                 100                         73                          0
  Brooker et al\[[@B59]\]         2003                14                    79                               20                                 100                         79                          0
  Morini et al\[[@B60]\]          2003                43                    67                               18                                 79                          42                          0
  Sabate et al\[[@B61]\]          2003                38                    68                               25                                 84                          53                          3
  Thomas-Gibson et al\[[@B62]\]   2003                59                    90                               18                                 73                          41                          3
  Singh et al\[[@B63]\]           2005                17                    35                               20                                 100                         76                          18
  Aljouni et al\[[@B64]\]         2006                37                    37                               20                                 90                          87                          3
  Ferlitsch et al\[[@B65]\]       2006                46                    59                               20                                 85                          66                          4
  Nomura et al\[[@B66]\]          2006                16                    35                               20                                 94                          65                          6
  Foster et al\[[@B67]\]          2008                24                    41                               20                                 92                          NA                          13
  Hoffman et al\[[@B68]\]         2008                25                    57                               20                                 100                         52                          16
  Stienecker et al\[[@B69]\]      2009                25                    42                               18                                 97                          94                          3
  Mueller et al\[[@B70]\]         2010                55                    23                               18                                 95                          76                          2
  Thienpont et al\[[@B71]\]       2010\`              138                   84                               18                                 97                          76                          3
  Scimeca et al\[[@B72]\]         2011                37                    90                               20                                 84                          89                          0
  Gustavsson et al\[[@B51]\]      2012                178                   80                               25                                 89                          64                          11
  Karstensen et al\[[@B73]\]      2012                23                    24                               15                                 83                          74                          1.9
  De'Angelis et al\[[@B74]\]      2013                26                    52                               18                                 100                         93                          2
  Endo et al\[[@B75]\]            2013                30                    36                               20                                 94                          64                          10
  Honzawa et al\[[@B76]\]         2013                25                    21                               20                                 88                          62                          12
  Nanda et al\[[@B77]\]           2013                31                    100                              18                                 100                         45                          0
  Atreja et al\[[@B78]\]          2014                128                   48                               20                                 83                          67                          3
  Bhalme et al\[[@B79]\]          2014                79                    61                               20                                 95                          77                          0
  Hagel et al\[[@B80]\]           2014                77                    57                               20                                 55                          65                          10
  Krauss et al\[[@B81]\]          2014                20                    25                               18                                 100                         NA                          14
  Ding et al\[[@B82]\]            2016                54                    100                              20                                 89                          82                          2

Clinical efficacy was defined according to each study (*i.e*., resolution of obstructive symptoms after dilation with the avoidance of surgery or additional intervention). Technical success was defined by successful passage of the endoscope or colonoscope immediately after dilation. Clinical efficacy was defined as the resolution of obstructive symptoms after dilation with the avoidance of surgery. Major complications (calculated per number of dilations) included were perforations, bleeding, intra-abdominal abscesses or fistulas. NA: Not available.

In the setting of small bowel strictures not in reach of the enteroscope or colonoscope, the double balloon enteroscope can be used in an antegrade or retrograde fashion for diagnostic and/or therapeutic intervention\[[@B15]\]. Although there are only a few small studies which have evaluated its use in dilating small bowel CD strictures, the results were positive\[[@B18],[@B19]\]. Nishida et al\[[@B20]\] performed a retrospective review on their center's experience with dilating small bowel strictures between 2006 to 2015. Overall, small bowel dilation using the double balloon enteroscope was found to be successful but there was a greater risk for requiring surgery in patients with multiple strictures as compared to those with a single stricture (adjusted hazard ratio, 14.94; 95%CI: 1.91-117.12; *P* = 0.010)\[[@B20]\]. As such, a single stricture but not necessarily multiple strictures may be a good indication for considering dilation using the double balloon enteroscope.

PREDICTORS OF SUCCESSFUL ENDOSCOPIC DILATATION
==============================================

Factors that are predictive of a successful EBD include short straight strictures in-line with the bowel lumen distal to the duodenum, which are non-ulcerated in a location without any adjacent abscess and at least 5 cm from a fistula orifice\[[@B21],[@B22]\]. Strictures located in the duodenum were found to have a 5 fold increased hazard for time to shorter surgery as compared to strictures located in the jejunum/ileum or colon (HR = 4.7, *P* = 0.038; HR = 5.6, *P* = 0.03; respectively)\[[@B23]\]. Additionally, a stricture length ≤ 5 cm was associated with a lower chance of requiring surgical intervention following EBD (HR = 2.5, 95%CI: 1.4-4.4; *P* = 0.002). For every 1 *cm* increase in stricture length, the risk for surgery increased by 8% (*P* = 0.005)\[[@B23]\]. In contrast to popular belief, anastomotic strictures have been associated with poorer short-term outcomes than *de novo* strictures\[[@B23],[@B24]\]. This was highlighted in the aforementioned review by Bettenworth et al\[[@B14]\] which documented a lower technical success rate for post-surgical strictures as compared to native strictures (OR = 2.3, *P* \< 0.001). Similarly, a recent study published by the Cleveland Clinic group after performing a retrospective review on 307 patients who had undergone either EBD or surgical resection for an ileocolonic anastomotic stricture had worse short-term outcomes (*i.e*., technical success) but similar long-term outcomes as compared to the aforementioned studies evaluating EBD of *de novo* strictures\[[@B24]\]. Of the 176 patients who had undergone EBD, the technical success rate was 86% (range 71% to 100%) with a long-term clinical efficacy, defined as an avoidance of surgery, of 58% over a follow-up period of 33 mo\[[@B24]\]. The presence of active inflammation identified on endoscopy, elevated CRP, medical treatment after dilation, cigarette smoking and intralesional steroid injection have demonstrated conflicting results with respect to the need for surgery and successful EBD\[[@B2],[@B17],[@B23],[@B24]\].

ENDOSCOPIC ADJUVANT TECHNIQUES
==============================

Intralesional injection of steroids has been demonstrated to be effective for peptic, corrosive, anastomotic or post-radiotherapy fibrotic strictures\[[@B25]\]. However, strong evidence for the use of intralesional injection of steroids in CD is lacking\[[@B25]-[@B28]\]. Studies that have evaluated its use in CD have used the formulation triamcinolone due to its rapid onset of action and long-lasting duration of effectiveness of 3-4 wk\[[@B29]\]. Only two small randomized placebo controlled studies have been performed evaluating the use of intralesional steroids versus saline injection after failing medical therapy and EBD. The first study conducted in 2007, included 13 adult patients with short (≤ 5 cm) ileocolonic anastomotic strictures\[[@B30]\]. Five of the seven patients in the intervention group required re-dilation after the procedure and one patient had a complication versus one of six in the placebo group required re-dilation. There was no significant difference with respect to success of the procedure between groups\[[@B30]\]. This trial was stopped early due to the trend toward harm and remains the influential study behind the current American College of Gastroenterology and British Society of Gastroenterology position statements against the routine use of intralesional steroids\[[@B31],[@B32]\]. The second study published in 2010 included 29 pediatric patients with short ileal or colonic strictures (12 anastomotic, 17 *de novo*)\[[@B33]\]. In contrast, this study did demonstrate a reduction in time to re-dilation and surgery in the intervention group. Within the sub-group of patients evaluated in a recent large systematic review evaluating the management of CD strictures, intralesional steroid injection did not improve outcomes\[[@B33]\]. Similarly, a review conducted in 2013 summarizing the findings from five retrospective case-series evaluating the use of intralesional steroids in CD patients concluded the data to be contradictory and limited\[[@B34]\].

Although controversial, intralesional injection of anti-tumor necrosis factor has been evaluated in patients with small bowel and colonic CD strictures with promising results, but concerns related to immunization may limit its potential as a therapeutic option\[[@B35],[@B36]\]. One small case series evaluated the effect of a 90-120 mg intralesional injection of infliximab in three symptomatic patients with colonic CD strictures. All three patients had an improved endoscopic appearance of the stricture as well as relief of their obstructive symptoms for at least four months following the injection\[[@B35]\]. Similarly, another small case series evaluating intralesional injections of 40 mg of infliximab into small bowel CD strictures combined with EBD in six patients was associated with improved symptoms and a reduction in their modified simple endoscopic score for Crohn's disease (SES-CD)\[[@B37]\]. The results of a larger randomized controlled trial evaluating the efficacy of performing intralesional injections of adalimumab into intestinal CD strictures are awaited\[[@B38]\].

Endoscopic metal stent insertion has been attempted in few patients with CD strictures. Although the technical success rate has been reportedly high, major complications such as bowel perforation, stent migration and fistulization was reported in 67% of patients\[[@B39]\]. Additionally, in order to avoid stent impaction, most studies suggest removing the stent after one month\[[@B40]-[@B42]\]. One small prospective cohort study concluded the risk for complications was too high to suggest the use of endoscopic metal stents as a treatment option for CD strictures after evaluating the data from 11 patients at their center\[[@B40]\]. The use of biodegradable instead of metal stents has been evaluated recently in a case-series last year involving six patients with intestinal and colonic CD strictures. Although technical success was good, premature stent failure occurred in all of the patients\[[@B43]\].

SAFETY OF ENDOSCOPIC BALLOON DILATION
=====================================

Although EBD is a minimally invasive procedure, bowel perforation and severe bleeding has been reported in most large studies\[[@B17],[@B23],[@B24]\]. In the aforementioned review by Bettenworth et al\[[@B14]\], major complications requiring hospitalization occurred in 2.8% of patients. Similarly, another large systematic review evaluating 24 non-randomized studies including 1163 patients found the rate of iatrogenic perforation to be 3%\[[@B44]\]. The rate for major complications including infection and hemorrhage in this study was 4%\[[@B44]\]. In a study directly comparing EBD to surgical intervention for the management of intestinal CD strictures, perforation occurred in 1.1% of the patients in the EBD group whereas the post-operative complication rate (*e.g*., intra-abdominal sepsis) was 8.8%\[[@B24]\]. Despite these significant complications, no deaths have been reported to date. Since benign or inflammatory intestinal strictures are indistinguishable from early adenocarcinoma on imaging, there exists a risk that malignancy may be missed when EBD is performed instead of surgical excision\[[@B3]\]. Population based studies have suggested a greater risk for small bowel malignancy in patients with longstanding CD. Several case reports exist documenting the development of small bowel malignancy following stricturoplasty and bypassed loops\[[@B45]-[@B51]\]. As such, biopsies of the stricture should occur prior to dilation\[[@B22]\]. There has been no evidence to suggest obtaining biopsies prior to EBD increases the risk for perforation.

CONCLUSION
==========

EBD remains a safe and effective modality of treating CD strictures in appropriately selected patients. Although it may not be able to prevent operative management in all patients, it can significantly delay it. For an isolated intestinal fibrostenotic CD stricture less than or equal to 5 cm in length without adjacent fistulization or perforation, EBD should be considered as first-line therapy (Table [3](#T3){ref-type="table"}).

###### 

Practical considerations

  ------------------------------------------------------------------------------- -------------------------------------------------------------------
  Predictors favoring successful dilation\[[@B11],[@B22]-[@B25]\]                 Symptomatic predominantly fibrotic stricture
  Short (≤ 5 cm) stricture                                                        
  Single straight stricture                                                       
  Stricture distal to the duodenum                                                
  Anastomotic stricture more favorable than de novo stricture                     
  First dilation                                                                  
  Lack of a superimposed process contributing to symptoms (*e.g*., SIBO or IBS)   
  Risk factors for complications\[[@B22]-[@B25]\]                                 Predominantly inflammatory stricture without medical optimization
  Stricture greater than 5 cm                                                     
  Multiple small bowel strictures                                                 
  Strictures caused by extrinsic compression (*e.g*., adhesions)                  
  Fistulization within 5 cm of the area to be dilated                             
  Adjacent perforation or intra-abdominal collection                              
  Complete small bowel obstruction                                                
  Tortuous or tethered small bowel or significant stricture angulation            
  Duodenal stricture                                                              
  [1](#T3FN1){ref-type="table-fn"}Short term outcome\[[@B15],[@B18]\]             85%-95% (technical success), 70%-80% (clinical response)
  [2](#T3FN2){ref-type="table-fn"}Long term outcome\[[@B15],[@B18]\]              32% (year 1 post dilation), 80% (year 5 post dilation)
  [3](#T3FN3){ref-type="table-fn"}Complication rate\[[@B25],[@B45]\]              1%-4%
  ------------------------------------------------------------------------------- -------------------------------------------------------------------

Short term outcome refers to the time elapsed immediately after the dilation takes place; technical success refers to the ability to successfully complete the dilation; clinical response refers to the symptomatic improvement of the patient immediately following the dilation;

Long term outcome refers to the percentage of patients requiring a repeat intervention;

Complication rate encompasses only major complications requiring urgent intervention such as bleeding, perforation and infection.
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